natgillin/translations-raw huggingface dataset:
In female smokers exposure (AUCinf) to ADASUVE and its active metabolite 7-OH-loxapine is lower than in female non-smokers (84% vs 109% 7-OH-loxapine/Loxapine Ratio), which is probably due to an increase in loxapine clearance in smokers. 
Pri kadilkah je izpostavljenost (AUCinf) zdravilu ADASUVE in njegovemu aktivnemu metabolitu 7OH-loksapinu nižja kot pri nekadilkah (84 % v primerjavi s 109 % razmerja 7-OH-loksapin/loksapin), do česar najverjetneje prihaja zaradi povečanega očistka loksapina pri kadilcih.
ADASUVE may have limited effectiveness when patients are on concomitant medicinal products, predominantly other antipsychotics. 
Zdravilo ADASUVE ima lahko omejeno učinkovitost, ko bolniki sočasno jemljejo druga zdravila, predvsem druge antipsihotike.
Joan Buscalla, 1-9, 08173 Sant Cugat del Vallès Barcelona, Spain 
Joan Buscalla, 1-9, 08173 Sant Cugat del Vallès Barcelona, Španija
Correct use of ADASUVE inhaler is important for administration of the full dose of loxapine. 
Pravilna uporaba inhalatorja ADASUVE je pomembna za dajanje polnega odmerka loksapina.
Patients had significant and long-standing psychiatric disease (Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)), based on years since diagnosis and previous hospitalizations. 
Bolniki so imeli očitno in dolgotrajno psihiatrično bolezen (Priročnik za diagnostiko in statistiko duševnih motenj; Diagnostic and Statistical Manual of Mental Disorders, 4. izdaja (DSM-IV)), na podlagi let od postavljene diagnoze in predhodnih hospitalizacij.
Because of the potential for sedation/somnolence, fatigue, or dizziness, patients should not operate hazardous machines, including motor vehicles, until they are reasonably certain that loxapine has not affected them adversely (see section 4.8). 
Ker loksapin lahko povzroči sedacijo/zaspanost, utrujenost ali omotičnost, bolniki ne smejo upravljati nevarnih strojev, vključno z motornimi vozili, dokler niso utemeljeno prepričani, da nanje loksapin ni imel neželenih učinkov (glejte poglavje 4.8).
In the two Phase 3 studies patients were enrolled who had acute agitation of at least moderate level (14 or higher on Positive and Negative Syndrome Scale (PANSS) Excited Component (PEC) scale (poor impulse control, tension, hostility, uncooperativeness, and excitement). 
V dve študiji faze 3 so bili vključeni bolniki z akutno agitiranostjo vsaj zmerne stopnje (14 ali več po lestvici pozitivnih in negativnih sindromov (Positive and Negative Syndrome Scale − PANSS) po lestvici komponent razburjenosti (Excited Component - PEC) (slab nadzor nad impulzi, napetost, sovražnost, nepripravljenost sodelovati in razburjenost).
Concomitant administration of benzodiazepines or other hypnosedatives or respiratory depressants may be associated with excessive sedation and respiratory depression or respiratory failure. 
Sočasno dajanje benzodiazepinov ali drugih hipnosedativov ali respiratornih zaviralcev je lahko povezano s prekomerno sedacijo in respiratorno depresijo ali odpovedjo dihanja.
Adrenaline should not be used since its use in a patient with partial adrenergic blockage may further lower the blood pressure (see sections 4.4 and 4.5). 
Adrenalin se ne sme uporabiti, saj bi njegova uporaba pri bolniku z delnim zaviranjem adrenergičnih receptorjev lahko še bolj znižala krvni tlak (glejte poglavji 4.4 in 4.5).
Ferrer Internacional, S.A. Gran Vía Carlos III, 94 08028- Barcelona España 
Ferrer Internacional, S.A. Gran Vía Carlos III, 94 08028- Barcelona Španija
• (Bipolar disorder) Feeling “high”, having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas, and sometimes severe irritability. 
• (bipolarna motnja) „privzdignjeno” razpoloženje, pretirana energija, zmanjšana potreba po spanju, hitro govorjenje s prehitevajočimi mislimi in občasno hujša razdražljivost.
Primary endpoint was absolute change in PEC score from baseline to 2 hours following Dose 1 for both doses of ADASUVE compared with placebo. 
Primarni opazovani dogodek je bila absolutna sprememba na lestvici PEC od izhodišča do 2 ur po prvem odmerku za oba odmerka zdravila ADASUVE v primerjavi s placebom.
Metabolites are excreted in the urine in the form of conjugates and in the faeces unconjugated. 
Metaboliti se izločijo z urinom v obliki konjugatov in z blatom v nekonjugirani obliki.
Becoming familiar with ADASUVE: The pictures below show the important features of ADASUVE. 
Spoznavanje zdravila ADASUVE: Spodnje slike prikazujejo pomembne posebnosti zdravila ADASUVE.
• adrenaline 
• adrenalin;
Κύπρος Τhespis Pharmaceutical Ltd Tηλ: 
Κύπρος Τhespis Pharmaceutical Ltd
Mean peak plasma concentrations were similar after the first and third dose of ADASUVE, indicating minimal accumulation during the 4-hour dosing interval. 
Povprečne najvišje plazemske koncentracije so bile podobne po prvem in po tretjem odmerku zdravila ADASUVE, kar kaže na minimalno kopičenje v 4-urnem intervalu odmerjanja.
However, loxapine and its metabolites have been shown to be transported into the milk of lactating dogs. 
Za loksapin in njegove metabolite so dokazali prehajanje v mleko doječih psic.
AUC0-2h, AUCinf, and Cmax increased in a dose-dependent manner. 
Vrednosti AUC0-2h, AUCinf in Cmax so naraščale v odvisnosti od odmerka.
Female rats did not mate due to persistent diestrus after oral treatment with loxapine. 
Samice podgan se niso parile zaradi dolgotrajnega diestrusa po peroralnem zdravljenju z loksapinom.
Other medicines and ADASUVE 
Druga zdravila in zdravilo ADASUVE
Patients with acute respiratory signs/symptoms (e.g., wheezing) or with active airways disease (such as patients with asthma or chronic obstructive pulmonary disease [COPD] (see section 4.4). 
Bolniki z znaki/simptomi akutnih motenj dihanja (npr. sopenjem) ali z aktivno boleznijo dihalnih poti (kot so na primer bolniki z astmo ali kronično obstrukcijsko pljučno boleznijo [KOPB]) (glejte poglavje 4.4).
A third dose was administered if needed after at least 4 hours after dose 2. 
Tretji odmerek je bil dan po potrebi in vsaj 4 ure po drugem odmerku.
• A clear recommendation not to start ADASUVE treatment in patients with a respiratory medical history 
• jasno priporočilo, da se pri bolnikih z anamnezo dihalnih težav ne sme začeti zdravljenja z zdravilom ADASUVE,
The green light turns on indicating that the inhaler is ready for use. 
Zasveti zelena lučka, ki kaže, da je inhalator pripravljen na uporabo.
• Treatment with ADASUVE to be limited to a hospital setting 
• zdravljenje z zdravilom ADASUVE mora biti omejeno na bolnišnično okolje,
How to use ADASUVE 4. 
Kako uporabljati zdravilo ADASUVE 4.
Seizures have been reported in patients receiving oral loxapine at antipsychotic dose levels, and may occur in epileptic patients even with maintenance of routine anticonvulsant drug therapy (see section 4.5). 
O napadih so poročali pri bolnikih, ki so prejemali loksapin peroralno v ravneh antipsihotičnih odmerkov, in se lahko pojavijo pri epileptikih, tudi če prejemajo vzdrževalno zdravljenje z rutinskimi odmerki antikonvulzivov (glejte poglavje 4.5).
• The indicator light turns on (green) when the tab is pulled out. 
• Signalna lučka se prižge (zeleno), ko je jeziček izvlečen.
• any breathing symptoms such as wheezing, cough, shortness of breath, or chest tightness, as these could mean that the medicine is irritating your airways (uncommon occurrence unless you have asthma or COPD); 
• kakršne koli dihalne simptome, kot so sopenje, kašelj, kratka sapa ali občutek tiščanja v prsnem košu, saj bi lahko pomenili, da zdravilo draži vaše dihalne poti (občasni pojav, razen če imate astmo ali KOPB);
Among the other endpoints were PEC and Clinical Global ImpressionImprovement (CGI-I) responders at 2 hours after dose 1, and total number of patients per group who received 1, 2, or 3 doses of study medication with and without rescue medication. 
Med drugimi opazovanimi dogodki so bili odzivi na lestvici PEC in lestvici kliničnega vtisa o izboljšanju (Clinical Global ImpressionImprovement (CGI-I)) v 2 urah po prvem odmerku in skupno število bolnikov na skupino, ki so prejemali 1, 2 ali 3 odmerke študijskega zdravila z in brez olajševalnega zdravila.
What you need to know before you use ADASUVE 
Kaj morate vedeti, preden boste uporabili zdravilo ADASUVE
No significant inhibition was observed. 
Pomembnega zaviranja niso opazili.
Severe extrapyramidal reactions should be treated with anticholinergic antiparkinson medicinal products or diphenhydramine hydrochloride, and anticonvulsant therapy should be initiated as indicated. 
Hude ekstrapiramidne reakcije je treba zdraviti z antiholinergičnimi antiparkinsonskimi zdravili ali z difenhidraminijevim kloridom, začeti pa je treba tudi z zdravljenjem z antikonvulzivi, kot je navedeno.
Very common: dysgeusia 
Zelo pogosti: disgevzija
Responders were considered patients with a ≥40% decrease from baseline in the total PEC score or patients with CGI-I score of 1 (very much improved) or 2 (much improved). 
Za bolnike z odzivom so bili upoštevani bolniki z ≥ 40 % znižanjem od izhodišča glede na skupni rezultat PEC ali bolniki z rezultatom na CGI-I 1 (zelo veliko izboljšanje) ali 2 (veliko izboljšanje).
Loxapine is metabolised extensively in the liver, with multiple metabolites formed. 
Loksapin se izdatno presnavlja v jetrih, pri čemer se tvorijo številni metaboliti.
• When ADASUVE is removed from the pouch, the indicator light is off. 
• Ko zdravilo ADASUVE vzamete iz vrečke, je signalna lučka ugasnjena.
Main results of the pivotal efficacy studies: comparisons between ADASUVE 4.5 mg, 9.1 mg, and placebo 
Glavni rezultati ključnih študij učinkovitosti: primerjave med zdravilom ADASUVE 4,5 mg, 9,1 mg in placebom
The possibility of occurrence of extrapyramidal symptoms and/or convulsive seizures should be kept in mind. 
Upoštevati je treba tudi možnost pojava ekstrapiramidnih simptomov in/ali epizod epileptičnih napadov.
Should bronchospasm occur after treatment with ADASUVE, it can be treated with a short-acting beta-agonist bronchodilator, e.g., salbutamol (see sections 4.2 and 4.8). 
Če po zdravljenju z zdravilom ADASUVE pride do bronhospazma, ga je mogoče zdraviti s kratkotrajno delujočim bronhodilatatorjem tipa agonistov beta-adrenergičnih receptorjev, npr. s salbutamolom (glejte poglavji 4.2 in 4.8).
ADASUVE with alcohol Because ADASUVE affects the nervous system, alcohol should be avoided when using ADASUVE. 
Ker zdravilo ADASUVE vpliva na živčni sistem, se morate izogibati alkoholu, kadar uporabljate zdravilo ADASUVE.
Do not drive or use any tools or machines after using ADASUVE until you know how ADASUVE affects you since dizziness, sedation, and sleepiness have been reported as a potential side effect of ADASUVE. 
Vpliv na sposobnost upravljanja vozil in strojev Po uporabi zdravila ADASUVE ne vozite in ne uporabljajte orodij ali strojev, dokler ne boste vedeli, kako zdravilo ADASUVE na vas deluje, saj so poročali o omotičnosti, sedaciji in zaspanosti kot o morebitnih neželenih učinkih zdravila ADASUVE.
No loxapine specific human data on fertility are available. 
Na voljo ni nobenih podatkov o plodnosti, specifičnih za ljudi.
No dosage adjustment is recommended based on smoking status. 
Za prilagajanje odmerka glede kajenja ni priporočil.
PEC Responders = > 40% change from PEC Baseline; CGI-I Responders = Score of 1 (Very Much Improved) or 2 (Much Improved) PBO = placebo SD=Standard Deviation 
Bolniki z odzivom PEC = > 40 % sprememba od izhodišča PEC; Bolniki z odzivom CGI-I = rezultat 1 (zelo veliko izboljšanje) ali 2 (veliko izboljšanje) PBO = placebo SD = standardni odklon
As would be expected from the pharmacologic actions of loxapine, the clinical findings may range from mild depression of the CNS and cardiovascular systems to profound hypotension, respiratory depression, and unconsciousness (see section 4.4). 
Kot je pričakovati glede na farmakološko delovanje loksapina, lahko klinične ugotovitve segajo od blage depresije osrednjega živčevja in srčno-žilnega sistema do izrazite hipotenzije, respiratorne depresije in nezavesti (glejte poglavje 4.4).
Embryo/fetal developmental and perinatal studies have shown indications of developmental delay (reduced weights, delayed ossification, hydronephrosis, hydrourether, and/or distended renal pelvis with reduced or absent papillae) as well as increased numbers of perinatal and neonatal deaths in offspring of rats treated from mid-pregnancy with oral doses below the maximum recommended human dose for ADASUVE on a mg/m basis (see section 4.6). 
Študije razvoja zarodkov/plodov in perinatalne študije so pokazale znake razvojnega zaostanka (manjšo maso, zakasnelo osifikacijo, hidronefrozo, hidroureter in/ali razširjen ledvični meh z zmanjšanimi ali odsotnimi papilami) kot tudi povečano število perinatalnih in neonatalnih poginov pri podmladku podgan, zdravljenih od sredine brejosti dalje s peroralnimi odmerki pod najvišjim priporočenim odmerkom zdravila ADASUVE za človeka na podlagi mg/m
• ADASUVE should be used with caution in patients who are intoxicated or delirious. 
• Zdravilo ADASUVE je treba pri bolnikih, ki so zastrupljeni ali v deliriju, uporabljati previdno.
• Antipsychotic medicines like ADASUVE can cause movements that you may not be able to control including making faces, sticking out your tongue, smacking or puckering your lips, blinking rapidly, or moving your legs, arms or fingers rapidly. 
• Antipsihotiki, kot je zdravilo ADASUVE, lahko povzročijo gibe, ki jih morda ne bosti mogli nadzirati, vključno z grimasami, iztegovanjem jezika, cmokanjem ali šobljenjem ustnic, hitrim mežikanjem ali hitrim premikanjem nog, rok ali prstov.
ADASUVE contains the active substance loxapine, which belongs to a group of medicines called antipsychotics. 
Zdravilo ADASUVE vsebuje učinkovino loksapin, ki spada v skupino zdravil, imenovanih antipsihotiki.
Note: If the green light stays on after the patient inhales, instruct the patient to repeat steps 3 to 5. 
Opomba: Če zelena lučka po vdihu še vedno gori, bolniku svetujte, naj ponovi korake 3 do 5.
MedDRA system organ classification Nervous system disorders 
Razvrstitev po organskih sistemih v skladu s sistemom MedDRA Bolezni živčevja
Loxapine is a substrate for flavin-containing mono-oxygenases (FMOs), and for several CYP450 isozymes (see section 5.2). 
Loksapin je substrat za monooksigenaze, ki vsebujejo flavin (FMO-ji), in za številne izocime CYP450 (glejte poglavje 5.2).
Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. 
Dodatni znaki lahko vključujejo zvišane vrednosti kreatinske fosfokinaze, mioglobinurijo (rabdomiolizo) in akutno odpoved ledvic.
ADASUVE should be used with caution in patients who are intoxicated or delirious (see section 4.5). 
Zdravilo ADASUVE je treba pri bolnikih, ki so zastrupljeni ali v deliriju, uporabljati previdno (glejte poglavje 4.5).
The recommended initial dose is 9.1 mg. After 2 hours, your doctor may prescribe a second dose after carefully considering your condition and your dose may be reduced to 4.5 mg if your doctor believes that this is a more appropriate dose to treat your condition. 
Po 2 urah vam zdravnik lahko predpiše drugi odmerek, ko temeljito preuči vaše stanje, odmerek pa lahko tudi zmanjša na 4,5 mg, če presodi, da je za zdravljenje vašega stanja to ustrezneje.
General disorders and administration site conditions Common: fatigue 
Splošne težave in spremembe na mestu aplikacije Pogosti: utrujenost
• Availabilty of rescue medications (short acting beta agonist bronchodilator) during treatment 
• razpoložljivost olajševalnih zdravil (kratkotrajno delujoči bronhodilatator tipa agonistov beta-adrenergičnih receptorjev) med zdravljenjem,
• ADASUVE is provided in a sealed pouch. 
• Zdravilo ADASUVE je dobavljeno v zapečateni vrečki.
Patients who have been given more ADASUVE than they should may experience any of the following symptoms: extreme tiredness or sleepiness, trouble breathing, low blood pressure, throat irritation or a bad taste in the mouth, muscle or eye movements you can't control. 
Bolniki, ki so prejeli večji odmerek zdravila ADASUVE, kot bi smeli, lahko občutijo katerega koli od naslednjih simptomov: izredna utrujenost ali zaspanost, težave z dihanjem, nizek krvni tlak, draženje žrela ali slab okus v ustih, premiki mišic ali očesa, ki jih ne morejo nadzirati.
After the first dose, a second dose was administered at least 2 hours later if the agitation had not subsided sufficiently. 
Drugi odmerek je bil dan vsaj 2 uri po prvem odmerku, če se agitiranost ni zadovoljivo zmanjšala.
Uncommon: dystonia, dyskinesia, oculogyration, tremor, akathisia/restlessness 
Občasni: distonija, diskinezija, okulogiracija, tremor, akatizija/nemir
• have or had glaucoma (increased pressure in the eye) 
• imate ali ste imeli glavkom (povišan tlak v očesu);
A study of inhaled loxapine and intramuscular lorazepam 1 mg in combination found no significant effects on respiratory rate, pulse oximetry, blood pressure, or heart rate compared with either drug administered alone. 
Študija kombinacije inhaliranega loksapina in intramuskularnega lorazepama 1 mg ni pokazala pomembnih učinkov na frekvenco dihanja, pulzno oksimetrijo, krvni tlak ali srčni utrip v primerjavi s samostojno uporabo katerega od teh zdravil.
If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, ADASUVE must be discontinued. 
Če se pri bolniku pojavijo znaki in simptomi, ki kažejo na nevroleptični maligni sindrom, ali ima nerazložljivo visoko telesno temperaturo brez dodatnih kliničnih znakov nevroleptičnega malignega sindroma, je treba zdravljenje z zdravilom ADASUVE prekiniti.
You should not breast-feed for a period of 48 hours after receiving ADASUVE and should discard the milk produced in the meantime. 
Svetujemo vam, da ne dojite v obdobju 48 ur po prejemu zdravila ADASUVE in da zavržete mleko, ki nastane v tem času.
Caution should be used in patients receiving concomitant treatment with other medicinal products that are either inhibitors or inducers of these enzymes, particularly if the concomitant medicinal product is known to inhibit or induce several of the enzymes involved in loxapine metabolism. 
Previdnost je potrebna pri bolnikih, ki prejemajo sočasno zdravljenje z drugimi zdravili, ki so bodisi zaviralci ali induktorji teh encimov, še posebej, če je za sočasno zdravilo znano, da zavira ali inducira več encimov, ki sodelujejo pri presnovi loksapina.
There were no important differences in the exposure or disposition of loxapine following administration of ADASUVE due to age, gender, race, weight, or body mass index (BMI). 
V izpostavljenosti ali razporeditvi loksapina po dajanju zdravila ADASUVE ni bilo opaziti pomembnih razlik glede na starost, spol, raso, telesno maso ali indeks telesne mase (ITM).
8-OH-loxapine is not pharmacologically active at the D2 receptor while the minor metabolite, 7-OH-loxapine, has high binding affinity to D2 receptors. 
8-OH-loksapin ni farmakološko aktiven na receptorju D2, medtem ko ima stranski metabolit, 7-OH-loksapin, visoko vezavno afiniteto za receptorje D2.
Each inhaler is packaged in a sealed foil pouch. 
Vsak inhalator je pakiran v zapečateno vrečko iz folije.
In short-term (24-hour), placebo-controlled trials in patients with agitation associated with schizophrenia or bipolar disorder without active airways disease, bronchospasm (which includes reports of wheezing, shortness of breath or cough) was uncommon in patients treated with ADASUVE. 
V kratkoročnih (24-urnih) kliničnih preskušanjih, ki so bila nadzorovana s placebom in opravljena pri bolnikih z agitiranostjo, povezano s shizofrenijo ali bipolarno motnjo brez aktivne bolezni dihal, bronhospazem (ki vključuje poročila o sopenju, kratki sapi ali kašlju) pri bolnikih, zdravljenim z zdravilom ADASUVE, ni bil pogost.
FERRER INTERNACIONAL, S.A. Joan Buscalla, 1-9, 08173 Sant Cugat del Vallès, Barcelona, Spain 
FERRER INTERNACIONAL, S.A. Joan Buscalla, 1-9, 08173 Sant Cugat del Vallès, Barcelona, Španija
Adrenaline should not be used, since beta-adrenoceptor stimulation may worsen hypotension in the setting of loxapine-induced partial alpha-adrenoceptor blockade (see section 4.5). 
Adrenalin se ne sme uporabiti, saj lahko stimulacija beta-adrenergičnih receptorjev poslabša hipotenzijo ob pojavu delnega zaviranja alfaadrenergičnih receptorjev, povzročenega z loksapinom (glejte poglavje 4.5).
In addition, in vitro studies indicate that loxapine and 8-OH loxapine are not inhibitors of UGT1A1, 1A3, 1A4, 2B7 and 2B15. 
Poleg tega študije in vitro nakazujejo, da loksapin in 8-OH-loksapin ne inhibirata UGT1A1, 1A3, 1A4, 2B7 in 2B15.
In studies in agitated patients, bronchospasm was reported as an uncommon, but serious adverse reaction, while in subjects with active airways disease, bronchospasm was commonly reported and often required treatment with a short-acting beta-agonist bronchodilator. 
V študijah z agitiranimi bolniki so o bronhospazmu poročali kot o občasnem, a resnem neželenem učinku, medtem ko so pri bolnikih z aktivno boleznijo dihalnih poti o bronhospazmu pogosto poročali in je ta večkrat zahteval zdravljenje s kratkotrajno delujočim bronhodilatatorjem tipa agonistov betaadrenergičnih receptorjev.
Firmly pull the plastic tab from the rear of the inhaler. 
Močno potegnite plastični jeziček z zadnjega konca inhalatorja.
NOTE: If the green light stays on after the patient inhales, instruct the patient to repeat steps 3-5. 
OPOMBA: Če zelena lučka po vdihu še vedno gori, bolniku svetujte, naj ponovi korake 3−5.
The most commonly reported adverse reactions during treatment with ADASUVE were dysgeusia, sedation/somnolence and dizziness (dizziness was more common after placebo treatment than loxapine treatment). 
Najpogostejši neželeni učinki, o katerih so poročali med zdravljenjem z zdravilom ADASUVE, so bili disgevzija, sedacija/zaspanost in omotičnost (omotičnost je bila pogostejša po zdravljenju s placebom kot po zdravljenju z loksapinom).
Additional side effects which have been related to long term use of loxapine by mouth and which may be relevant for ADASUVE include faintness upon standing, increased heart rate, increased blood pressure, blurred vision, dry eyes, and decreased urination. 
Dodatni neželeni učinki, ki so bili povezani z dolgotrajno peroralno uporabo loksapina in ki so lahko pomembni za zdravilo ADASUVE, vključujejo vrtoglavico ob vstajanju, povišano srčno frekvenco, povišan krvni tlak, zamegljen vid, suhe oči in zmanjšano uriniranje.
• have or had heart problems or stroke 
• imate ali ste imeli težave s srcem ali ste doživeli srčno kap;
For complete instructions on how to use ADASUVE see information for the healthcare professional section of the package leaflet. 
Za celotna navodila o uporabi zdravila ADASUVE glejte informacije v poglavju za zdravstvenega delavca v navodilu za uporabo.
Loxapine is a substrate for several CYP450 isozymes; in vitro studies demonstrated that 7-OHloxapine is formed mainly by CYPs 3A4 and 2D6, 8-OH-loxapine is formed mainly by CYP1A2, amoxapine is formed mainly by CYP3A4, 2C19, and 2C8, and loxapine N-oxide is formed by FMOs. 
Loksapin je substrat za številne izocime CYP450; študije in vitro so pokazale, da se 7-OH-loksapin tvori predvsem s CYP-ji 3A4 in 2D6, 8-OH-loksapin se tvori predvsem s CYP1A2, amoksapin se tvori predvsem s CYP3A4, 2C19 in 2C8, loksapin N-okside pa se tvori s FMO-ji.
ADASUVE has not been studied in elderly patients, including those with dementia-related psychosis. 
Zdravilo ADASUVE ni bilo preučeno pri starejših bolnikih, vključno s tistimi, ki imajo psihozo, povezano z demenco.
• ADASUVE may cause narrowing of the airways (bronchospasm) and may cause you to wheeze, cough, feel chest tightness or have shortness of breath. 
• Zdravilo ADASUVE lahko povzroči zoženje dihalnih poti (bronhospazem) ter povzroči sopenje, kašelj, občutek tiščanja v prsnem košu ali kratko sapo.
Potential for ADASUVE to affect other medicinal products 
Morebiten vpliv zdravila ADASUVE na delovanje drugih zdravil
Co-administration of loxapine and adrenaline may cause worsening of hypotension (see section 4.4). 
Sočasno dajanje loksapina in adrenalina lahko povzroči poslabšanje hipotenzije (glejte poglavje 4.4).